HK Stock Market Move | QYUNS-B (02509) rose more than 8% in early trading. QX027N has obtained two clinical trial implicit licenses and is intended for the treatment of asthma and atopic dermatitis.

QYUNS-B (02509) rose more than 8% in early trading, and as of the time of writing, it was up 8.45% to HKD 22.08, with a trading volume of 5.603 million Hong Kong dollars. On the news front, QX027N injection, a long-acting dual anti-drug independently developed by Qianxin Biotech, obtained the clinical trial implied license from the Drug Evaluation Center of the National Medical Products Administration for the treatment of asthma and atopic dermatitis. The clinical license for this candidate drug marks the company's innovative dual anti-matrix in the field of self-immunity and allergic diseases officially entering the clinical stage. It is worth noting that on October 28, Qianxin Biotech announced a global exclusive cooperation and licensing agreement with Roche for its independently developed long-acting dual anti-QX031N. Under the agreement, Roche will be granted the global exclusive rights for research, development, registration, production, and commercialization of QX031N. Qianxin Biotech will receive an upfront payment of $75 million, as well as up to $995 million in milestone payments, and gradient royalty fees on potential future product sales.